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Abstract
Background and  Objective:  FRAX  is  the  most  widely  used tool for the assessment of the risk of osteoporotic fractures. The first
country-specific FRAX model for Ukraine, calibrated to the total Ukrainian population, was developed in October, 2016. This study aimed
to describe the output of the Ukrainian FRAX model and to illustrate its  features  compared  to  models  for  neighbouring  countries.
Materials and Methods: The development of the Ukrainian model of FRAX was based on two regional epidemiological studies in Ukraine
[Vinnitsa city (1997-2002), STOP-study (Uzhgorod city and Vinnitsa area, 2011-2012)], which were performed to derive the incidence of
hip fractures in men and women. The construct of the FRAX model for Ukraine required the beta coefficients for risk factors in the original
FRAX model and the age and sex-specific incidence rates of hip fracture and mortality for Ukraine. Results: As expected, 10 year
probability of hip or major osteoporotic fractures was increased in patients with a clinical risk factor (CRF), female gender, higher age,
lower BMI and decreased BMD T-score. Of the CRFs, a prior fracture had greatest effect in the age group 50-70 years and parental hip
fracture accounted for the greatest increase in 10-year fracture probability in the age group 80-90 years. Conclusion: The Ukrainian FRAX
tool is the first country-specific fracture prediction model available in Ukraine which is based on the original FRAX® methodology, that
has been externally validated in several independent cohorts. Despite some limitations, the strengths make the Ukrainian FRAX tool a
good candidate for implementation into clinical practice.
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INTRODUCTION
Osteoporosis is an important skeletal disease
characterized by low bone mass and microarchitectural
deterioration of bone tissue with a resulting increase in bone
fragility and ‘low trauma’ fractures. Based on measures of bone
mineral density (BMD) in Caucasians, osteoporosis is present
in 15% of those 50-59 years of age and its frequency rises
markedly to 70% in those over 80 years of age1. Osteoporosis-
related fractures are major cause of morbidity and mortality
and health expenditure worldwide. According to recent data,
22 million women and 5.5 million men in Europe were
estimated to have osteoporosis in 2010 and 3.5 million new
fragility fractures were sustained, comprising 610000 hip
fractures, 520000 vertebral fractures, 560000 forearm fractures
and 1800000 other osteoporotic fractures2. For these reasons,
predicting the absolute risk of osteoporotic fractures is of the
utmost importance to optimize prevention strategies3.
Current evidence suggests that BMD is an important but
far from perfect criterion to determine fracture risk. Indeed,
many fractures arise in patients with osteopenia or BMD
values  within  the   normal  range4-6.  Fortunately,  other
clinical risk factors (CRF), such as age, prior fracture, lifestyle,
co-morbidities etc., contribute independently to the risk of
osteoporotic fractures. Study of their association with
osteoporosis and fractures have stimulated the development
of large databases to define the impact of each of the CRFs on
the risk of vertebral and non-vertebral fractures. This approach
subsequently led to the development of several tools for risk
assessment of osteoporotic fractures7. Those available on line
include FRAX®, the Garvan fracture risk calculator and
QFracture®8-10. Over 100 clinical practice guidelines include
FRAX in their recommendations, making it the most widely
used fracture prediction tool worldwide8.
FRAX was developed by the former World Health
Organization Collaborating Centre for Metabolic Bone
Diseases at Sheffield, UK and first released in 200711. The
algorithm  calculates fracture probability from readily
obtained clinical risk factors in women and men
(http://www.shef.ac.uk/FRAX).  The  output  of  FRAX  is   the
10 year probability of a major osteoporotic fracture (hip,
clinical spine, humerus or wrist fracture) and the 10 year
probability of hip fracture. The framework used considers
competing mortality and avoids biased over-estimates in older
individuals and those with risk factors for increased death12.
Probability is calculated from age, sex, body mass index (BMI)
and dichotomized risk factors comprising prior fragility
fracture, parental history of hip fracture, current tobacco
smoking, long-term oral glucocorticoid use, rheumatoid
arthritis, other causes of secondary osteoporosis and excessive
alcohol consumption. Femoral neck BMD can be optionally
input to enhance fracture risk prediction13.
Current evidence suggests that there are regional
variations in osteoporotic fracture risk14  and to a much lesser
extent, in BMD. Indeed, greater than 10-fold difference in hip
fracture incidence has been reported in different countries. For
this reason, FRAX models are calibrated to take into account
of national variations in fracture risk (and death risk).
The required information to build a FRAX model,
particularly the epidemiology of fracture incidence, is not
available in all countries. In such cases, the use of a surrogate
model has been proposed using the death rate of the index
country and the fracture rate of a country thought to be
similar to the index country in terms of fracture risk15.
Alternatively, clinicians can use a neighbouring country model
where the risks of fracture and death are assumed to be similar
and, since 2009, the Ukrainian Scientific Medical Centre on
Osteoporosis Problems (Kiev) has used the FRAX algorithms to
estimate the osteoporotic fracture risk16,17. Rather than
developing a surrogate model, the Austrian version of FRAX
was adopted for clinical practice18. Recently, data have
become available on hip fracture incidence in the Ukraine and
a country-specific model was developed in 201719. The aim of
the present study was to determine the characteristics of the
Ukrainian FRAX model.
MATERIALS AND METHODS
The development and validation of FRAX have been
extensively described8,11. The risk factors used were based on
a systematic set of meta-analyses of population based cohorts
worldwide and  validated  in independent cohorts with over
1 million patient-years of follow-up. The construct of the FRAX
model for Ukraine required the beta coefficients for risk factors
in the original FRAX model and the age and sex-specific
incidence rates of hip fracture and mortality for Ukraine. The
relative importance of the beta coefficients for fracture was
assumed to be similar in Ukraine  as  that  determined by
meta-analysis. With regard to fracture, the development of the
Ukrainian model of FRAX was based on two regional
epidemiological studies in Ukraine [Vinnitsa city (1997-2002),
STOP-study (Uzhgorod city and Vinnitsa area, 2011-2012)], to
derive the incidence of hip fractures in men and women, aged
40 years and above19,20. Mortality risk used data from the
United Nations21.
For the present report, estimates of fracture probability
were calculated with body mass index set at 25 kg/m2, unless
otherwise  indicated.  The  impact of FRAX CRFs and a range of
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(a)T-scores were examined on the probability of hip and major
osteoporotic fractures in men and women. Values for Ukraine
were compared with data from neighbouring countries where
a FRAX model was available22-25.
RESULTS
Fracture probability without BMD: The 10 year probability of
major osteoporotic fractures and hip fracture in Ukrainian
women and men increased progressively with age (Fig. 1). For
both hip and major osteoporotic fractures, the probability of
hip fracture increased with age up to the age of 85 years and
decreased thereafter in women due to the competing effect
of mortality on the fracture hazard. As expected, probabilities
were consistently higher in women than in men.
Each of the CRFs influenced fracture probability
independently (Table 1). Weak risk factors for 10 year
probability of a major fracture included high alcohol intake
and current smoking. For example, at the age of 80 years,
alcohol use was associated with an increase in the probability
for a major fracture from 2.9 to only 3.9% in  men  and  from
6.7-8.9%  in  women.  Smoking  was  also  a  weak  risk factor
for fractures. Probability of major osteoporotic fractures
increased slightly in women, but probability of a major
osteoporotic fractures did not change markedly in men aged
from 50-70 years.
From the age of 80 years, parental history of major
osteoporotic fracture was  associated  with  the  highest  risk
in  men  and  women  (6.6 and 14.0%, respectively at  age  of
80 years). Below this age, large increments in fracture
probabilities in men and women were associated with a
history  of  prior  fractures   (4.8   and  11.0%,  respectively  at
80 years). Intermediate increments in probability were
associated with rheumatoid arthritis and long-term  use of
glucocorticoids (4.5 and 4.2% in men and 10.0% for both in
women, respectively) at the age of 80 years. 
Fracture probability with BMD:  When  BMD  was entered
into the FRAX model, the 10-year probability of a major
osteoporotic fracture increased with decreasing T-score in
men and women at any given age (Table 2). At all ages, the
fracture probability was higher in women than in men for a
given T-score. Whereas fracture probabilities increased with
age at younger ages, with advancing age, the same T-score
was associated with a lower fracture probability. For example,
at a T-score of -1 SD in women, the fracture probability was
lower at the age of 80 (2.5%) and 90 years (2.5%) than at the
age  of  70  years  (3.7%).  The  decreasing  probability  at  older
Fig. 1(a-b): Ten-year probability of a (a) Major osteoporotic
fracture (MOF) and (b) Hip fracture according to
age in Ukrainian women and men (No CRFs, FRAX
without BMD and BMI set to 25 kg/m2)
Table 1: Ten year probability of a major osteoporotic fracture (%) in men and
women according to the presence of CRFs in the absence of BMD
Age (years)
----------------------------------------------------------------------
CRFs 50 60 70 80 90
Men
None 2.2 2.3 2.4 2.9 3.0
Alcohol 2.6 2.8 3.0 3.9 4.2
Smoking 2.2 2.3 2.4 3.1 3.3
Rheumatoid arthritis 2.9 3.1 3.4 4.5 4.8
Glucocorticoids 3.3 3.4 3.5 4.2 4.4
Parental history 4.3 4.4 3.9 6.6 8.1
Prior fracture 4.7 4.7 4.6 4.8 4.7
BMI at 20 kg mG2 a 2.1 2.2 2.4 3.1 3.5
Women
None 3.1 4.0 5.0 6.7 6.0
Alcohol 3.7 4.9 6.4 8.9 8.3
Smoking 3.3 4.4 5.6 7.5 6.7
Rheumatoid arthritis 4.2 5.6 7.2 10.0 9.4
Glucocorticoids 5.1 6.6 8.2 10.0 8.9
Parental history 6.1 7.7 8.3 14.0 14.0
Prior fracture 6.7 8.3 9.6 11.0 9.7
BMI at 20 kg mG2 a 3.3 4.4 5.7 7.7 6.9
BMI is set at 25 kg/m2 except where indicated, aNo other CRF, CRF: Clinical risk
factors
9
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Table 2: Ten year probability of major osteoporotic fracture for women and men with a BMI of 25 kg/m2 according to age and BMD T-score for femoral neck BMD in
the absence of other CRFs
Age (years)
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
BMD Women Men
T-score ------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------
(SD) 50 60 70 80 90 50 60 70 80 90
0 2.9 3.1 2.9 2.6 1.7 2.2 2.0 1.7 1.5 1.1
-0.5 3.0 3.4 3.2 3.1 2.1 2.4 2.2 1.9 1.8 1.3
-1.0 3.4 3.7 3.7 3.6 2.5 2.8 2.6 2.2 2.0 1.5
-1.5 4.0 4.3 4.2 4.3 3.0 3.4 3.2 2.8 2.5 1.7
-2.0 4.8 5.3 5.2 5.2 3.6 4.3 4.0 3.5 3.1 2.0
-2.5 6.2 6.8 6.7 6.6 4.3 5.8 5.3 4.4 3.8 2.5
-3.0 8.5 9.0 8.8 8.6 5.5 8.3 7.1 5.8 4.8 3.0
-3.5 13.0 12.0 12.0 11.0 7.0 13.0 10.0 7.6 5.9 3.6
-4.0 19.0 18.0 16.0 15.0 8.9 20.0 14.0 10.0 7.5 4.3
Table 3: Ten year probability of a major osteoporotic fracture (hip, clinical spine, humerus or forearm) and a hip fracture calculated with the Ukrainian FRAX model
for women (BMI set at 25 kg/m2)
Age (years)
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------
50 55 60 65 70 75 80 85 90
Major osteoporotic fracture
No CRFs (A) 3.1 3.5 4.0 4.4 5.0 6.0 6.7 6.9 6.0
BMD T-score-2.5 SDa (B) 6.2 6.6 6.8 6.7 6.7 6.9 6.6 5.6 4.3
Probability ratio (B/A) 2.0 1.9 1.7 1.5 1.3 1.2 1.0 0.8 0.7
Previous fracture (C) 6.7 7.5 8.3 8.8 9.6 11.0 11.0 11.0 9.7
Probability ratio (C/A) 2.2 2.1 2.1 2.0 1.9 1.8 1.6 1.6 1.6
Hip fracture
No CRFs (D) 0.3 0.4 0.6 0.9 1.4 2.1 3.0 3.8 3.8
BMD T-score-2.5 SDa (E) 2.0 2.1 2.1 2.1 2.3 2.5 2.8 2.8 2.4
Probability ratio (D/E) 6.6 5.3 3.5 2.3 1.6 1.2 0.9 0.7 0.6
Previous fracture (F) 1.0 1.4 1.7 2.3 3.0 3.8 4.7 5.9 5.8
Probability ratio (F/D) 3.3 3.5 2.8 2.6 2.1 1.8 1.6 1.6 1.5
aNo other CRFs
ages results from the competing effect of BMD on mortality.
Similar results were seen in men, though the phenomenon of
decreasing probabilities occurred 10 years earlier in men than
in women.
Similar results were observed for the 10 year probability
of hip fracture in men and women (data not shown) in that
fracture probability increased with decreasing T-score but that
the same T-score yielded different probabilities at different
ages. For example, in men with a T-score of -3.5 SD, the hip
fracture probability was 9.2% at the age of 50 years but was
2.5% at the age of 90 years.
Intervention thresholds: In Ukraine, the  current  threshold
for the reimbursement of treatments is based on BMD
measurements by Dual-energy X-ray Absorptiometry (DXA)
with a treatment threshold set at -2.5  SD.  The  probabilities of
a major osteoporotic fracture equivalent to a T-score of -2.5 SD
are given for women in Table 3. Probabilities rose from 6.2% at
the age of 50-6.9% at the age of 75 years and subsequently
decreased. When these probabilities were compared to
women of the same age with no CRFs and without DXA, it was
evident that, at the age of 50 years, a T-score of -2.5 SD was
associated with a significantly higher probability compared to
women of the same age without CRFs (6.2 vs. 3.1%; probability
ratio = 2.0; Table 3). With advancing age, the probability ratio
fell progressively and reached unity at the age of 80 years.
Above this age, a T-score of -2.5 SD was associated with a
lower fracture probability compared to women of the same
age with no CRFs and without DXA. The explanation is that in
the oldest old, there is a decrease in the probability of fracture
because of the competing effect of death risk plus the
decrease in T-score with advancing age. Thus, the BMD
criterion for reimbursement using a fixed T-score became
progressively less appropriate with advancing age.
In the case of a prior fracture, major osteoporotic fracture
probabilities rose from 6.7% at the age of 50 to 11% at the age
of 75 years. When these probabilities were compared to
women of the same age with no CRFs and without DXA, it was
evident that, at the age of 50 years, a history of a prior fracture
was associated with a significantly higher probability
compared to women of the same age without CRFs (6.7 vs.
3.1%; probability ratio = 2.2; Table 3). With advancing age, the
probability ratio fell modestly with age but was greater than
unity at all ages. Similar observations were made in the case of
10
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Fig. 2: Probability of the hip fracture for women and men aged 50 years with a BMI set at 25 kg/m2 and BMD T-score for femoral
neck -2.5 SD in the absence of other CRFs
hip fracture probabilities. These considerations suggest that a
viable threshold for reimbursement might be the probability
equivalent of a prior fracture, in the absence of BMD.
Comparison with neighbouring countries: In Fig. 2, it gives
the 10-year probability  of  major osteoporotic  fracture and
hip fracture at the age of 65 years in women with BMI  set at
25 kg/m2 and BMD T-score for femoral neck of -2.5 SD in the
absence of other CRFs in the Ukraine and neighbouring
countries where a FRAX model was available. For major
osteoporotic fracture, there was a greater than three-fold
range in probabilities between countries. Of these countries,
Moldova, Slovakia and Russia had the higher fracture
probabilities. Intermediate values were noted for the Czech
Republic, Hungary and Romania. Probabilities of major
osteoporotic fracture for Ukraine were amongst the lowest
and similar to those for Poland and Belarus. Comparative data
for men are given in the supplementary table.
DISCUSSION
This present study describes the characteristics of a FRAX
model for the assessment of 10 year probability of major
osteoporotic fracture and hip fracture in the Ukrainian
population according to sex, age, BMD and CRFs. In the
absence of BMD, probabilities of a major fracture in the
Ukrainian population increased with age in men and women
up to the age of 85 years and decreased, thereafter, due to the
competing effect of  mortality  hazard  on  fracture  risk.  The
10 year absolute probability of any major osteoporotic and hip
fracture in the presence of a single risk factor increased with
advancing age in both sexes, being always higher in women
than in men. Each of the CRFs contributed independently to
fracture probability but with a different weight. Consistent
with other country-specific models, the Ukrainian model
identified a parental history of hip fracture as the strongest risk
factor; long-term use of glucocorticoids, rheumatoid arthritis
and a prior fragility fracture were associated with moderate
increments in probability.
Although fracture probability increases with decreasing
T-score, the relationship between probability and T-score was
not linear. Thus, at any given T-score, fracture probabilities did
not consistently rise with increasing age in women and men
(Table 2). Indeed, at the extremes of age (and T-score)
probabilities decreased. The declining fracture probability at
extreme old age is partly mediated by the increased and
competing risk of death in the general population, an effect
more marked in men than in women. Importantly, low BMD is
also associated with an increased risk of death, which is
captured in the FRAX algorithm11. This explains why the
declining fracture probability with age is much more marked
at low T-scores. This effect has implications for practice
guidelines. In Ukraine, as in many countries, the current
threshold for the reimbursement of treatments is based on
BMD  measurements  by DXA with the treatment threshold set
at a T-score of -2.5 SD. The present study confirms that the
BMD criterion for reimbursement using a fixed T-score
becomes less and less appropriate with advancing age. This
has been recognized in the development or the updating of
practice  guidelines which have taken more account of
fracture probability and  placed  less  reliance  on the T-score
for BMD8. The manner in which new guidelines have
accommodated probability-based assessment has been
heterogeneous, with some adopting fixed probability
threshold e.g. Canada26 as a component of pre-existing
guidelines e.g. Japan and the US27,28  others  have recommend
an age-dependent threshold equivalent to a fracture
threshold29-31   or    the    risks    associated    with     pre-existing
11
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guidelines for reimbursement32. The present study indicates
that age-dependent probability-based thresholds are more
appropriate than T-score thresholds.
A second intervention threshold that authors examined
was the risk equivalent to a woman with a prior fragility
fracture, predicated by the fact that many guidelines
recommend intervention in women with a prior fragility
fracture29. In line with guidelines for the UK and Europe, an
intervention threshold based on the ten-year probability of a
major osteoporotic fracture for a woman was examined with
a previous fracture. The intervention threshold is age-specific
and ranged from 6.7% at the age of 50 years up to 11% at the
age of 70 years. Thus, women who have a fracture probability
that is equal to or exceeding that of a woman with a prior
fracture would be eligible for treatment even in the absence
of a fracture history. Such approaches, first developed by the
National Osteoporosis Guideline Group (NOGG)31, have now
been widely adopted32.
The present study has several strengths and limitations.
A limitation is that the data on hip fracture rates, used to
develop FRAX, are based on regional, rather than national,
estimates. Thus, the FRAX model may not be representative
for the whole of Ukraine. Although the epidemiological
studies were able to minimize the over identification of cases
(double counting), they were not able to exclude pathological
fractures or assess the accuracy of reporting or coding of
fractures. There are also important limitations in the construct
of the FRAX model. Ideally, information is required on the
incidence of major fractures (hip, spine, forearm and
humerus).  In  contrast to hip  fractures,  the  incidence  of
other major fractures could not be determined because a
dedicated registry with routinely recorded osteoporotic
fractures does not exist in Ukraine. As undertaken for many
countries with incomplete  information,  the incidence of
these three types of osteoporotic fractures  was  imputed from
the hip fracture incidence in Ukraine and the relationship
between hip fracture incidence and that of the other sites in
Sweden3. This assumes that the ratio of hip fracture incidence
to the incidence of other index fractures is similar in Ukraine
and Sweden. This assumption, used in the development of
some FRAX models, appears to hold true for the several
countries where this has been tested15. Despite some
limitations, the strengths make the Ukrainian FRAX tool a good
candidate for implementation into clinical practice. It can be
recommended for widespread use in assessment of 10 year
probability of major osteoporotic fractures in the Ukrainian
population.
CONCLUSION
The Ukrainian FRAX tool is the first country-specific
fracture prediction model available in Ukraine. It is based on
the original FRAX methodology and Ukrainian epidemiological
data.
SIGNIFICANCE STATEMENT
This study allowed developing the Ukrainian version of
the FRAX model, calculating the national indices for men and
women and comparing them with indices of neighboring
countries. The Ukrainian model of FRAX can be used in
assessment of 10-year probability of major osteoporotic
fractures and hip fractures in the Ukrainian population.
Present study results allowed to determine the place of the
Ukrainian model among other European models of FRAX, to
calculate the national indices for men and women and to
compare them with the models of neighboring countries.
Earlier,   the   10-year   risk   of  osteoporotic  fractures
were determined using the Austrian model of FRAX (IOF
recommend to  do  it  when  it  is  not  possible  to  use
country-specific models). However, it has been shown that
Austrian model, like the models of other countries, can not be
recommended because it does not accurately calculate this
risk.
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